

Novo Nordisk

seeks partners within

hemostasis management
of hemophilia



Novo Nordisk is a focused healthcare company

We are headquartered in Denmark and have affiliates in 80 countries.

Novo Nordisk is a worldwide market leader in diabetes with

- A full portfolio of insulin analogs
- The broadest portfolio of insulin delivery systems and a leading position in the global injection device market.

Novo Nordisk has a leading position in

- Hemophilia with inhibitors
- Growth hormone disorders
- Hormone replacement therapy.

Changing possibilities in hemophilia

Novo Nordisk is expanding within hemophilia care management.

Our development of recombinant human Factor VIIa (rFVIIa) was a breakthrough for treating bleeding in hemophilia patients with inhibitors. We aim to lead innovation in hemophilia and improve access to care for all patients with hemophilia.

Our partnering focus

We seek partners and opportunities such that we can prevent and treat bleeding in people with hemophilia

- Improve therapies for patients with inhibitors
- Improve replacement therapies for patients with hemophilia A or B without inhibitors
- Develop novel non-replacement therapies that improve hemostasis for patients with hemophilia.

Our pipeline

Our R&D pipeline demonstrates our commitment to improve hemophilia care. We have novel derivatives, analogs and formulations of the critical clotting factors in both pre-clinical and clinical development to provide a comprehensive portfolio of products for people with hemophilia.




In 1986 Dr. Ulla Hedner initiated the FVIIa project to secure treatment for hemophilia patients with inhibitors.



Proteins from molecule to market

Our world-class protein competencies allow us to pursue ambitious goals. The clinical pipeline in hemophilia demonstrates our competencies within both producing and engineering complex proteins.



What do we offer our partners?

Our 85 year history tells us that creativity thrives in partnerships. And that one-size does not fit all. So, we actively engage in partnerships and are open to the full range of set-ups from in-licensing to sophisticated partnerships. There are three special reasons for choosing Novo Nordisk as your future partner

- Full, global value chain: Proteins from molecule to market
- Focus: Life-long dedication to patient care and our business
- Fairness: Decency is what counts.

Read much more at www.novonordisk.com/science/partnering



Contacts



Jørn Roland Müller, Corp. VP, e-mail: jrom@novonordisk.com



Dan Zekzer, Senior Sourcing Director, e-mail: daze@novonordisk.com



Thomas Hanke, Sourcing Director, e-mail: thnk@novonordisk.com



Anand Gautam, Sourcing Director, e-mail: agum@novonordisk.com